Emcure Subsidiary Acquires Class E Shares in Mantra Pharma for CAD $50M

Emcure Pharmaceuticals Ltd announced that its subsidiary, Marcan Pharmaceuticals Inc., has acquired all Class E Special Shares in its step-down subsidiary, Mantra Pharma Inc., for an aggregate consideration of CAD $50 million. The transaction, which occurred on July 02, 2026, ensures Mantra remains a 100% subsidiary of Marcan. Mantra Pharma Inc. is engaged in the marketing and distribution of prescription drugs and natural health products in Canada, with an annual turnover of CAD $96.67 million. This acquisition is considered a related party transaction between two wholly-owned subsidiaries and is being conducted on an arm's length basis. The deal is subject to completion of requisite compliances under Canadian law.